-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 20, Biotech announced that it had recently received the "Clinical Trial Approval Notice" for the drug under development BAT6005 injection approved and issued by the State Food and Drug Administration
BAT6005 is an anti-TIGIT monoclonal antibody of IgG1 subtype with normal Fc effect function developed by Biotech, which is intended to be developed for tumor treatment